Pharma & Healthcare

Covers pharmaceuticals, biotech, medical devices, diagnostics, healthcare systems, and increasingly AI applied to drug discovery and healthcare. Drug development is long, complex, and science-driven. Understanding the biology, chemistry, and clinical pipeline behind a company tells you more than its balance sheet. This category analyzes pharmaceutical and biotech opportunities through a science-first lens — from molecule to market — so you can read the opportunity before the stock price moves.

Why U.S. Health Care Costs So Much: The Reason, the Fix, and the Opportunity

U.S. health care spending hit $5.3 trillion in 2024 — more than any other country, despite the U.S. not even being the world's richest per capita. This piece breaks down the real reasons why (paperwork, physician pay, undernegotiated drug prices), how Germany, Japan, and Singapore keep costs down instead, which U.S. fixes are already underway, and where each of those dynamics creates a distinct opportunity for different types of investors.

Aug 9

How Pharma Bets on the Next Wave (Without Ever Really Knowing)

Mega-caps spend billions like they know where the next wave is. They don't. Here's what buying drilling rights in pharma actually looks like — and why even the best-positioned players still miss almost every time.

Aug 4

The Pharma Paradox: Predictable Markets, Unpredictable Winners

A known disease. A known market. So why does pharma investing still feel like guessing? The answer splits cleanly into what you can actually predict — and what stays a coin flip no matter how good the science looks.

Aug 4

How AI Increases the Odds a Failed Drug Becomes a Winner

Roughly 97.5% of drug candidates die before a patent is ever filed on them — invisible to competitors, regulators, and the public. This piece breaks down how AI is starting to mine that hidden graveyard, and why no single unpatented failure has turned into a headline win yet.

Jul 26

Pharma vs. Medtech ETFs: What You're Actually Buying

The medtech ETF beat the pharma ETF over the last decade — not because medtech won, but because two stocks inside it did. Here's what you're actually buying, and why the S&P 500 beat both anyway.

Jul 20

1,451 AI Medical Devices, Two Real Winners: The Truth About AI in Medtech

The FDA has cleared 1,451 AI medical devices since 1995. Only two have ever proven they actually change what happens to a patient — everything else has proven it's accurate, not that it matters.

Jul 19

The Medtech Moat AI Can't Easily Break

AI is changing medical technology in two opposite ways. Using Abbott's cardiovascular devices and Intuitive Surgical's robotic platform as case studies, this article shows how AI strengthens the core switching-cost moat while gradually eroding the vendor-specific software layer surrounding it.

Jul 19

AI Won't Save Medtech From Pharma — It Might Make the Gap Worse

Artificial intelligence is transforming both pharma and medtech—but not in the same way. This article explains why AI reinforces pharma's patent-based competitive advantage while offering only limited moat expansion for most medical device companies, and what that means for long-term investors.

Jul 19

Inside a Pharma Bet: From Science to Revenue

Casgevy's climb from $10 million to a projected half-billion in revenue looks like one decision. It's actually six — and the same stack explains almost any pharma company's next move.

Jul 16

The Acquirer's Playbook: How a Pharma VP Actually Chooses What to Buy

What actually happens inside a pharma company before a $10 billion acquisition gets announced? This piece maps the real decision framework — build vs. partner vs. buy, the screening checklist, and why a target's leverage is easy to underestimate — using real negotiations like Novartis's standoff with Avidity Biosciences.

Jul 15

2 3 4

Pharma & Healthcare

Why U.S. Health Care Costs So Much: The Reason, the Fix, and the Opportunity

How Pharma Bets on the Next Wave (Without Ever Really Knowing)

The Pharma Paradox: Predictable Markets, Unpredictable Winners

How AI Increases the Odds a Failed Drug Becomes a Winner

Pharma vs. Medtech ETFs: What You're Actually Buying

1,451 AI Medical Devices, Two Real Winners: The Truth About AI in Medtech

The Medtech Moat AI Can't Easily Break

AI Won't Save Medtech From Pharma — It Might Make the Gap Worse

Inside a Pharma Bet: From Science to Revenue

The Acquirer's Playbook: How a Pharma VP Actually Chooses What to Buy

Get New Tools and Insights

About Us

RichStorm